Generic Semaglutide: Lower-Cost Semaglutide is Here!
BUY NOW
We Ship To The U.S. Only
Retatrutide vs Tirzepatide
How Do These Next-Generation Weight Loss Medications Compare?
- Posted On:
- 11 Jun, 2026
- 16 min read
-
Mounjaro (Tirzepatide): A once-weekly injectable medication for adults with type 2 diabetes or obesity.Starting From $559.99 -
Zepbound KwikPen® (Tirzepatide)
Zepbound Injection Pens: A convenient and precise treatment for hemophilia B.Starting From $499.99
10% Off On Your First Order
Click on the Copy Code button to copy your code.
No Expiry
Exclusive On Duty Free Meds Only
GLP-1-based weight loss medications and metabolic medications have rapidly evolved and grown in popularity over the past 40 years. Among these types of medications are those such as tirzepatide – which is currently approved – and retatrutide – which is still considered to be an investigational medication. People often compare these two medications due to their comparable features for weight loss results and differing mechanisms of action. Patients may also compare these medications if they are considering switching to retatrutide once it becomes available. This article will explore the evidence-based insights available for each of these medications so far and take a deeper look into their similarities and differences.
-
Zepbound KwikPen® (Tirzepatide)
Zepbound Injection Pens: A convenient and precise treatment for hemophilia B.Starting From $499.99 - Mounjaro (Tirzepatide): A once-weekly injectable medication for adults with type 2 diabetes or obesity.Starting From $559.99
10% Off On Your First Order
Click on the Copy Code button to copy your code.
No Expiry
Exclusive On Duty Free Meds Only
- Tirzepatide is a well-established approved dual GIP and GLP-1 receptor agonist
- Retatrutide is a triple-agonist medication that is still in Phase 3 clinical trials and not yet approved
- Clinical trials so far show greater average weight loss with retatrutide compared to tirzepatide
- Both medications are once-weekly injections and share similar gastrointestinal side effects
- Retatrutide is not yet available for public use outside clinical trials
Retatrutide vs Tirzepatide Compared
Retatrutide is a novel medication under clinical investigation, recognized for its innovative mechanism as a triple-agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. These three receptor pathways play critical roles in metabolic regulation, influencing appetite, glucose metabolism, and energy expenditure. The combination of these effects positions Retatrutide as a promising candidate for addressing obesity, type 2 diabetes, and potentially other metabolic disorders. Retatrutide is still in the clinical trial phase, with ongoing research assessing its efficacy and safety.
| Category | Retatrutide | Tirzepatide |
|---|---|---|
| Drug Name | Retatrutide | Tirzepatide |
| Status | Investigational (in Phase 3 trials) | Approved |
| Receptor Targets | Triple agonist (targets GLP-1, GIP, and glucagon receptors) | Dual agonist (targets GIP and GLP-1 receptors) |
| Dosing Frequency | Once weekly | Once weekly |
| Dosing Range | Phase 3 obesity trials studying:
(May change upon approval) |
|
| Average Weight Loss Effectiveness | Average weight loss of approximately 28.7% of patients’ baseline body weight in clinical trials | Average weight loss of approximately 20.9% of patients’ baseline body weight in clinical trials |
| Common Side Effects |
|
|
| Availability / Regulatory Status | Not yet approved | Approved |
| Typical Use Cases | Currently in Phase 3 clinical trials for obesity and related metabolic conditions (not yet approved and not available for purchase) |
|
What Is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 agonist that is used for the treatment of type 2 diabetes and can be found under the name brand “Mounjaro.” This medication may also be used to help patients struggling with obesity lose weight when purchased under brand names such as Zepbound. This medication works by increasing patients’ insulin levels and improving their insulin sensitivity. It also reduces patients’ appetite – which helps them lose weight. The average weight loss in clinical trials was approximately 20.9% of patients’ baseline body weight. Clinical trials also showed that this medication made significant improvements to patients’ HbA1c and blood glucose levels.
What Is Retatrutide?
Retatrutide is a triple agonist medication – meaning it affects the GLP-1, GIP, and glucagon receptors – that is currently being studied for its potential use in obesity and metabolic issues treatment. It is also being studied for potential use in the treatment of type 2 diabetes. The addition of glucagon receptor activity may trigger increased energy expenditure – or thermogenesis – and lead to greater lipolysis compared to other single- or dual-hormone therapies. It can also lead to greater energy expenditure. Retatrutide data are still based on early-phase and emerging Phase 3 trials and long-term durability data are limited. This medication has not yet received official FDA approval and cannot yet be purchased.
This medication is still undergoing Phase 3 trials. However, the TRIUMPH-4 trial has shown that this medication has proven to have promising effects on reducing markers for cardiovascular risk and has helped patients participating in the recent study lose an average of about 28.7% of their body weight. Patients should be aware that retatrutide cardiovascular benefits are based on cardiometabolic markers only and there have been no completed cardiovascular outcomes trials yet. This medication also helped patients reduce their pain that occurred due to weight-related conditions – such as knee osteoarthritis.
Differences Between the Mechanism of Action
The dual action of tirzepatide allows the medication to reduce HbA1c levels for patients and lower fasting glucose. It also helps improve the patient’s insulin sensitivity. This makes the medication helpful for managing type 2 diabetes and reducing cardiovascular risks – such as high cholesterol and blood pressure. Retatrutide works a little bit differently since it is a triple-agonist medication. This makes its impact on blood sugar levels a little more complicated. However, this medication is still helpful for improving insulin sensitivity and glucose control. This medication can also be helpful for issues such as fatty liver disease.
The mechanisms of this medication may make it better suited for the treatment of metabolic issues and weight loss versus type 2 diabetes treatment. Glucagon receptor activation may increase energy‑expenditure and hepatic glucose output. Long-term metabolic impact remains under investigation. However, this mechanism may both increase weight loss and shift which tissues and side effects are stressed.
Comparing Weight Loss Results: Retatrutide vs. Tirzepatide
Retatrutide patients lost an average of approximately 28.7% of their baseline body weight in clinical trials. Patients using this medication were found to frequently lose over 70 lbs during the first year of using this medication. Studies showed that patients using tirzepatide lost an average of approximately 20.9% of their baseline body weight. Some patients using this medication lost over 25% of their body weight (more than 60 lbs) while taking the highest dose for over a year. Studies so far have also shown that retatrutide has a greater absolute weight reduction effect and helps patients lose weight at a quicker rate than tirzepatide.
Patients should keep in mind that the current data available about retatrutide is early and based purely on controlled trial populations. More or changing information may be available upon the drug’s release to the public. Specific results the patient will experience while taking the medication themselves may vary based on factors such as the dose and duration of use. Different patient characteristics also impact the results.
Comparison of Dosing and Administration
| Feature | Tirzepatide | Retatrutide |
| Dosing Frequency | Once Weekly | Once Weekly |
| Doses | Standardized dosing for Zepbound version:
Standardized dosing for Mounjaro version:
|
Note: These dosing amounts are based on what has been tested in current clinical studies. There is no standardized commercial dosing yet. They may change upon the drug’s approval and release. |
| Dosing Schedule |
| Titration varied based on the dosing group of the patients and the clinical trial they were participating in. |
Specific clinical guidance and precise doses are currently only available for tirzepatide. This is the only medication of the two that is available on the market and is available for purchase.
What Are the Differences Between Side Effects and Tolerability
Studies suggest that adverse effects may be more common with the use of higher doses of retatrutide compared to tirzepatide. However, these two medications have many shared side effects. Most of these side effects are related to gastrointestinal issues – such as diarrhea or constipation and nausea or loss of appetite.
Tirzepatide already has a known tolerability profile since it has already been approved and has been widely used. The information available for retatrutide is based on early safety data that has been gathered for clinical trials so far. There may be additional unknown side effects of this medication due to its glucagon activation. This medication has not yet been available for public use. It is important that patients using either of these medications gradually titrate their doses to allow their bodies time to get used to the medication and minimize their risk of experiencing side effects.
Tips For Switching From Tirzepatide to Retatrutide
The significant weight loss results shown for retatrutide in clinical studies so far have led some patients to consider switching to this medication once it becomes available. This medication is shown to have greater weight loss potential than medications like tirzepatide. However, patients should keep in mind that this medication is still not currently available outside clinical trials.
Patients who do decide to switch between these medications when it becomes available should keep track of when they have the last dose of their medication and may have to factor in a washout period if a doctor determines one is necessary. Doctors will likely have patients re-titrate their new medication when they start it as well. This gives the body a better chance to adjust to the new medication. Patients who are switching medications will also have to closely monitor their side effects to determine how the medication is affecting them and make sure it is safe to continue using it as planned. Any future switching between GLP-1 medications must be physician-directed once retatrutide is approved.
Comparing Cost, Availability and Regulatory Status
Tirzepatide
This medication has already been approved and is widely prescribed. A couple of different name-brand versions of it are available for purchase. The list price of Zepbound is $1,086.37 without any insurance coverage. The exact price may vary depending on where the patient purchases it from. The list price of Mounjaro is $1,112.16 for each fill without insurance coverage. The price patients pay for this medication may also vary by seller. Commercially insured patients with coverage can get this medication for as low as $25 per month (or as low as $499 if their insurance does not cover the medication).
Retatrutide
Retatrutide does not have a price yet because it can only be used within clinical trials and has not yet been made available for public purchase/use. Retatrutide costs will be announced upon the medication’s release. Approval for this medication is expected in 2027 with sales forecasted starting in 2031. The exact approval date is still uncertain and Phase 3 trials are still taking place.
Retatrutide vs. Tirzepatide Who Might Benefit More From Each Medication
Tirzepatide may be a suitable medication for patients who are looking for a therapy route that has already been proven to demonstrate safe and effective results. This medication is also associated with strong weight loss results. Retatrutide is not yet available and is still undergoing testing. However, it could be a potential future option for patients needing greater metabolic impact once it is approved and has been confirmed for safety. The best treatment option may be different for every patient and should be individualized on a case-by-case basis (as determined by the patient’s doctor).
Frequently Asked Questions
Is retatrutide better than tirzepatide?
Current clinical trials suggest that retatrutide may produce greater average weight loss (around 28.7% of body weight) compared to tirzepatide (around 20.9%). However, retatrutide is still investigational and long-term safety and real-world data are not yet available. Results may also be different depending on the patient.
Is it currently possible to transition from tirzepatide to retatrutide?
No. Switching is not possible outside of a clinical trial because retatrutide is not yet approved.
Why does retatrutide cause more weight loss in trials?
Tirzepatide targets two hormones (GLP-1 and GIP) and retatrutide targets three – the same two as tirzepatide plus glucagon. The added glucagon activity in retatrutide may increase energy expenditure and lipolysis – likely being the reason for the greater weight loss seen in early trials.
Are side effects worse with retatrutide?
Early clinical trial data suggest that higher trial doses showed increased gastrointestinal adverse events for this medication compared to tirzepatide. The side effect profiles are comparable for both medications. Researchers are still continuing to evaluate whether retatrutide should have any unique safety considerations since it also activates the glucagon receptor.
Will retatrutide replace tirzepatide?
It is unlikely that retatrutide would completely replace tirzepatide. The two medications may serve slightly different patient populations.
When will retatrutide be available?
Availability would follow FDA authorization and commercial launch if this medication is approved. Approval for this medication is expected in 2027 with sales forecasted starting in 2031. The exact approval date is still uncertain and Phase 3 trials are still taking place.
Can I buy retatrutide?
No. Retatrutide is currently in Phase 3 clinical trials and has not yet received FDA approval. It cannot be legally prescribed or purchased outside of approved research studies.
Conclusion
Tirzepatide is a proven and approved dual-agonist medication that is currently available for both type 2 diabetes and chronic weight management. Retatrutide is a promising investigational triple-agonist that has shown impressive weight-loss results in clinical trials. However, this medication is still in Phase 3 trials and has not yet been approved for use. Weight loss results still appear to be greater with the use of this medication so far. Long-term safety and availability are still unknown. It is important to follow the evidence of any medication before use and consult healthcare professionals to determine the best fit for them rather than following current trends.
Purchase more affordable medications today – including weight loss medications like Mounjaro or Zepbound (Tirzepatide) – from Duty Free Meds.
Sources
Disclaimer: The information presented here is intended solely for educational purposes and should not be interpreted as medical advice, a diagnosis, or specific treatment recommendations. It does not imply endorsement of any particular medication or therapy. Health conditions and treatment responses can differ significantly between individuals; thus, this information is not a guarantee of safety, suitability, or effectiveness for anyone in particular. Always seek the guidance of a healthcare professional for personalized medical advice and consult them before making any health or treatment decisions.
